Harbour Biomed
Shanghai · Founded 2016
About Harbour Biomed
Harbour BioMed is a developer of bio-therapeutics aimed at immuno-oncology and inflammatory diseases. The company engages in discovery and development programs that are centered around two patented transgenic mouse platforms for generating both fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb) based immune cell engager (HBICETM) bispecific antibodies, thereby enabling medical professionals to generate potential therapeutic antibodies and accelerate drug discovery and development.
Company Facts
- Founded: 2016
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $417.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2025)
- Ticker: hkg:2142
- Website: https://www.harbourbiomed.com/
- Phone: +86-21-51370990
Industries & Categories
Biopharma, Biotechnology, Oncology, Pharmaceutical
Investment Activity
- 1 exit(s) (1 via IPO)
Social Profiles
Canonical: https://fsome.com/organization/harbour-biomed-34743 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.